Skip to main content

Table 1 Baseline characteristics of study participants

From: Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial

Characteristic

ASā€‰+ā€‰DP

Nā€‰=ā€‰79

ASā€‰+ā€‰AL

Nā€‰=ā€‰71

QNNā€‰+ā€‰DP

Nā€‰=ā€‰71

QNNā€‰+ā€‰AL

Nā€‰=ā€‰79

Female (%)

36 (45.6)

36 (50.7)

24 (33.8)

37 (46.8)

Age in monthsa

17 (11ā€“26)

16 (10ā€“26)

17 (13ā€“26)

18 (13ā€“26)

Weight (kgs)a

9.5 (8ā€“11.5)

9 (8.1ā€“11)

9.8 (8.8ā€“11)

9.2 (8.4ā€“11)

Temperature (degrees Centigrade)a

38.8 (37.7ā€“39.5)

39.1 (37.7ā€“39.5)

39.1 (37.3ā€“39.5)

38.6 (37.5ā€“39.6)

Parasite density per uL, log10 copiesa

4.82 (4.29ā€“5.10)

4.79 (4.38ā€“5.02)

4.72 (4.19ā€“5.00)

4.73 (4.17ā€“5.03)

Complications at admission, n (%)

ā€ƒHemoglobin (mg/dL)a

9.1 (7.9ā€“10.5)

9.2 (8.4ā€“10.6)

9.3 (8.4ā€“10.4)

9.4 (8.0ā€“10.3)

ā€ƒTotal white blood cell count (a103/uL)a

9.6 (6.9ā€“13.2)

9.2 (7.5ā€“12.3)

9.4 (7.7ā€“12.1)

10.0 (7.0ā€“14.3)

ā€ƒRandom blood sugar (mmol/L)a

7.3 (6.3ā€“8.3)

6.8 (6.4ā€“8.3)

6.8 (5.7ā€“8.3)

7.4 (6.25ā€“8.25)

ā€ƒHistory of repeated convulsions n (%)

6 (7.6%)

3 (4.2%)

8 (11.3%)

1 (1.3%)

ā€ƒHistory of inability to feed

26 (33.0%)

24 (34.0%)

22 (31.0%)

29 (36.7%)

ā€ƒProstration (extreme weakness)

22 (27.9%)

15 (21.13%)

21 (29.58%)

21 (26.58%)

ā€ƒHemoglobinuria

0

0

2 (2.8%)

0

ā€ƒJaundice

2 (2.5%)

0

3 (4.2%)

3 (3.8%)

ā€ƒSevere anemia

0

0

1 (3%)

2 (2.5%)

ā€ƒRespiratory distress

2 (2.5%)

6 (8.5%)

3 (4.2%)

5 (6.3%)

ā€ƒImpaired consciousness

0

0

1 (1.4%)

0

ā€ƒAbnormal bleeding

2 (2.5%)

1 (1.4%)

0

1 (1.3%)

ā€ƒHypoglycemia

0

0

0

1 (1.3%)

  1. aValues are presented as medians (IQR)